

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA)

RRID:AB_2629749

Type: Antibody

Proper Citation

BioLegend Cat# 138429, RRID:AB_2629749

Antibody Information

URL: http://antibodyregistry.org/AB_2629749

Proper Citation: BioLegend Cat# 138429, RRID:AB_2629749

Target Antigen: KLRG1

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA)

Description: This monoclonal targets KLRG1

Target Organism: mouse, human

Clone ID: Clone 2F1/KLRG1

Antibody ID: AB_2629749

Vendor: BioLegend

Catalog Number: 138429

Record Creation Time: 20250820T042117+0000

Record Last Update: 20250820T184440+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA).

No alerts have been found for Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Grassmann S, et al. (2026) Stepwise epigenetic signal integration drives adaptive programming of cytotoxic lymphocytes. *Immunity*, 59(2), 339.

Cortez VS, et al. (2025) IL-25-induced memory type 2 innate lymphoid cells enforce mucosal immunity. *Cell*.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Mujal AM, et al. (2025) Splenic TNF- γ signaling potentiates the innate-to-adaptive transition of antiviral NK cells. *Immunity*, 58(3), 585.

Harris RJ, et al. (2025) OMIP-119: A 36-Color Full-Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Peripheral Blood and Ex Vivo Expanded Human T Cells. *Cytometry. Part A : the journal of the International Society for Analytical Cytology*, 107(12), 787.

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. *iScience*, 28(8), 113147.

Fang X, et al. (2025) The m6A reader HNRNPC is a key regulator in DSS-induced colitis by modulating macrophage phenotype. *iScience*, 28(3), 111812.

Cortez VS, et al. (2025) IL-25-induced memory ILC2s mediate long-term small intestinal adaptation. *bioRxiv : the preprint server for biology*.

Linger ME, et al. (2025) Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice. *iScience*, 28(10), 113479.

Das A, et al. (2024) Transcription factor Tox2 is required for metabolic adaptation and tissue residency of ILC3 in the gut. *Immunity*, 57(5), 1019.

Chen DG, et al. (2024) Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer. *Cell reports*, 43(3), 113872.

López DA, et al. (2024) Prenatal inflammation remodels lung immunity and function by programming ILC2 hyperactivation. *Cell reports*, 43(7), 114365.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8⁺ T cells exhibit molecular heterogeneity and differential dependence on Eomes. *Immunity*, 56(1), 207.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. *Cell reports. Medicine*, 4(3), 100939.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. *Cell reports*, 42(1), 111937.

Dutt TS, et al. (2022) Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. *Cell reports*, 41(11), 111783.

Hanna BS, et al. (2021) Interleukin-10 receptor signaling promotes the maintenance of a PD-1^{int} TCF-1⁺ CD8⁺ T cell population that sustains anti-tumor immunity. *Immunity*, 54(12), 2825.

Dammeijer F, et al. (2020) The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. *Cancer cell*, 38(5), 685.